期刊文献+

重组百日咳杆菌黏附素蛋白免疫小鼠可完全抵抗支气管败血波氏杆菌的致死性感染 被引量:3

Protecting mice from fatal Bordetella bronchiseptica infection by immunization with recombinant pertactin antigens
下载PDF
导出
摘要 【目的】通过建立的小鼠呼吸道感染模型评价重组百日咳杆菌黏附素蛋白(GST-PRN)对小鼠的免疫保护效力。【方法和结果】在主动免疫保护试验中,GST-PRN免疫组小鼠能产生较高的PRN抗体水平,在使用3×LD50的支气管败血波氏杆菌HH0809株进行呼吸道气雾攻毒后,其保护率为100%(20/20),但载体蛋白GST和PBS对照组小鼠的存活率仅为15%(3/20)和20%(4/20)。在被动免疫保护试验中,腹腔免疫GST-PRN兔抗血清能100%(10/10)保护小鼠抵抗10×LD50的HH0809株的腹腔攻击,但GST兔抗血清和PBS免疫组小鼠的存活率均为0(0/10和0/9)。【结论】研究结表明重组PRN蛋白具有良好的免疫学活性,可作为亚单位疫苗或疫苗添加成分。 [Objective] We evaluated the efficacy of the recombinant pertactin (PRN)-specific active or'passive immunization against Bordetella bronchiseptica (Bb) in an aerosol challenge model established by using BALB/c mice. [Methods and results] Mice, immunized subcutaneously with two doses of purified glutathione S-transferase (GST)-PRN protein mixed with an equal volume of Freund's adjuvant, produced robust PRN-specific IgG antibody activity. All 20 mice vaccinated with GST-PRN protein survived aerosol challenge with three times the 50% lethal dose (LD50) of virulent Bb HH0809 compared with 3 of 20 GST protein-treated controls and 4 of 20 PBS-treated controls that survived. Furthermore, we observed complete protection against intraperitoneal challenge with ten times the LD50 of virulent HH0809 strain in mice that were injected intraperitoneally with 0.5 ml rabbit anti-GST-PRN serum. No survivors were observed in mice that received either rabbit anti-GST serum or PBS alone. [Conclusion] The recombinant PRN protein had strong immunogenicity against Bb infection.
出处 《微生物学报》 CAS CSCD 北大核心 2008年第3期337-341,共5页 Acta Microbiologica Sinica
基金 国家自然科学基金(30471292) 国家“863计划”(2006AA10A206)~~
关键词 支气管败血波氏杆菌 百日咳杆菌黏附素 免疫原性 Bordetella bronchiseptica pertactin immunogenicity
  • 相关文献

参考文献14

  • 1Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other BordeteUa subspecies. Clin Microbiol Rev, 2005, 8(2): 326-382.
  • 2Baysinger A. PRDC: is it new or deja vu?. Pork, 1999, 19: 64.
  • 3De Jong MF. Progressive and nonprogressive atrophic rhinitis. In: Straw BE, d'Allaire S, Mengeling WL, et al. (eds.). Diseases of swine. Ames, IA: Iowa State University Press, 1999.
  • 4蔡宝祥.家畜传染病学.第三版.北京:中国农业出版社,2002.
  • 5Backstrom L. Present uses of and experiences with swine vaccines. Adv Vet Med, 1999, 41: 419-428.
  • 6United States Department of Agriculture. Part Ⅰ: reference of swine health and management in the United States, 2000. National Animal Health Monitoring System, 2001, 338: 39-48.
  • 7United States Department of Agriculture. Part Ⅱ: reference of swine health and management in the United States, 2000. National Animal Health Monitoring System, 2002, 355: 29-36.
  • 8Montaraz JA, Novomy P, Ivanyi J. Identification of a 68-kilodalton protective protein antigen from Bordetella bronchiseptica. Infect Immun, 1985, 47:744-751.
  • 9Novotny P, Kobisch M, Cownley K, et al. Evaluation of Bordetella bronchiseptica vaccines in specific-pathogen free piglets with bacterial cell surface atigens in enzyme-linked immunosorbent assay. Infect Immun, 1985, 50:190-198.
  • 10Novomy P, Chubb AP, Cownley K, et al. Adenylate cyclase activity of a 68,000-molecular-weight protein isolated from the outer membrane of Bordetella bronchiseptica. Infect Immun, 1985, 50(1): 352-357.

二级参考文献29

  • 1刘国平,吴斌,刘梦元,何启盖,唐先春,郭黎明,黄晓东,陈焕春.致仔猪水肿病大肠杆菌的分离、鉴定及生物学特性[J].中国兽医学报,2005,25(1):31-33. 被引量:26
  • 2刘国平,吴斌,林艺远,金梅林,陈焕春,赵战勤,汤细彪,杨明柳.大肠杆菌Ee株SLT-ⅡeB基因的3拷贝融合表达及其生物学活性与免疫原性[J].微生物学报,2007,47(4):686-691. 被引量:5
  • 3吴斌 陈焕春 何启盖.应用乳胶凝集试验进行猪传染性萎缩性鼻炎血清流行病学调查[J].中国兽医科技,2001,31(6):21-22.
  • 4Fraser M E, Fujinaga M, Chemey M M, Melton-Celsa A R, Twiddy E M, O'Brien A D and James M N. Structure of shiga toxin type 2 (Stx2) from Escherichia coli O157:H7 (J). The Journal of Biological Chemistry, 2004, 279 (26): 27511-27517
  • 5Koitabashi T, Vuddhakul V, Radu S, Morigaki T, Asai N, Nakaguchi Y and Nishibuchi M. Genetic characterization of Escbericbia coli O157: H7/- strains carrying the stx2 gene but not producing Shiga toxin 2 (J). Microbiology and Immunology, 2006, 50(2):135-148
  • 6MacLeod D L and Gyles C L. Purification and characterization of an Escherichia coli Shiga-like toxin II variant (J).Infection and Immurdty, 1990, 58(5):1232-1239
  • 7Persson B and Argos P. Prediction of transmembrane segments in proteins utilising multiple sequence alignments(J). Journal of Molecular Biology, 1994, 237:182-192
  • 8Sambrook J, Fritsch E F and Maniatis T. Molecular Cloning: A Laboratory Manual(M). Beijing: Science Press, 1998.
  • 9Saxena S K, O'Brien A D and Ackerman E J. Shiga toxin, Shiga-like toxin Ⅱ variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes (J). The Journal of Biological Chemistry, 1989, 264(1):596-601
  • 10Schmitt C K, McKee M L and O'Brien A D. Two copies of Shiga-like toxin Ⅱ -related genes common in enterohemorrhagic , strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511(J). Infection and Immunity, 1991, 59 (3): 1065-1073

共引文献9

同被引文献27

  • 1徐引弟,郭爱珍,刘维红,贾爱卿,陈焕春.猪霍乱沙门氏菌C500株△crp△asd缺失株平衡致死载体系统的构建及鉴定[J].生物工程学报,2006,22(3):366-372. 被引量:31
  • 2Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989.
  • 3Helen SG, Katherine AB, Richard WT. Salmonella vaccine for use in humans: present and future perspectives. FEMS Micro Rev, 2002, 26(3): 339-353.
  • 4Roy Curtiss III. Bacterial infectious disease control by vaccine development. J Clin Invest, 2002, 110(8): 1061-1066.
  • 5Mattoo S, Cherry J. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev, 2005, 18(3): 326-382.
  • 6Leininger E, Bowen S, Renauld-Mongenie G, et al. Immunodominant domains present on the Bordetella pertussis vaccine component filamentous hemagglutinin. J Infect Dis, 1997, 175(5): 1423-1431.
  • 7Knight JB, Huang YY, Halperin SA, et al. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Clin Exp Immunol, 2006, 144(3): 543-551.
  • 8Hellwig SM, Rodriguez ME, Berbers GA, et al. Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis, 2003, 188(10): 738-742.
  • 9Novotny P, Kobisch M, Cownley K, et al. Evaluation of Bordetella bronchiseptica vaccines in specific-pathogen- free piglets with bacterial cell surface antigens in enzyme-linked immunosorbent assay. Infect Immun, 1985, 50(1): 190-198.
  • 10Hijnen M, Mooi FR, van Gageldonk PG, et al. Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun, 2004, 72(7): 3716-3723.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部